UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000019460
Receipt No. R000022495
Official scientific title of the study A study for the effect of intake of a plant extracts containing drink on skin conditions and vascular functions.
Date of disclosure of the study information 2015/11/02
Last modified on 2016/10/21 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study A study for the effect of intake of a plant extracts containing drink on skin conditions and vascular functions.
Title of the study (Brief title) A study for the effect of intake of a plant extracts containing drink on skin conditions and vascular functions.
Region
Japan

Condition
Condition Dry skin
Classification by specialty
Dermatology Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objective of this study is to evaluate the effects of intake of the plant extract containing drink on skin conditions and vascular function
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Measurement of vascular function,

(measurement time : 0, 30, 60, 90, 120 mins after ingestion of the test drink)
Key secondary outcomes Measurement of skin condition,
Observation of skin texture,

(measurement time : 0, 30, 60, 90, 120 mins after ingestion of the test drink)

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Single blind -participants are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment No need to know

Intervention
No. of arms 3
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Ingestion of a bottle of placebo drink at the evaluation day. After 7 days, ingestion of two bottles of test drink at the evaluation day. Furthermore, 7 days later, ingestion of a bottle of test drink at the evaluation day.
Interventions/Control_2 Ingestion of two bottles of test drink at the evaluation day. After 7 days, ingestion of a bottle of test drink at the evaluation day. Furthermore, 7 days later, ingestion of a bottle of placebo drink at the evaluation day.
Interventions/Control_3 Ingestion of a bottle of test drink at the evaluation day. After 7 days, ingestion of a bottle of placebo drink at the evaluation day. Furthermore, 7 days later, ingestion of two bottles of test drink at the evaluation day.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
25 years-old <=
Age-upper limit
35 years-old >=
Gender Female
Key inclusion criteria 1. Healthy female aged from 25 to 35 years old
2. Persons who have felt mental stress for recent 1 or 2 months.
3. Persons who have skin troubles.
4. Menstrual cycle is stable at 25 to 30 days.
5. BMI is from 18.5 to 25.0
Key exclusion criteria 1. Persons who are outpatients or were treated by doctor recently.
2. Persons who are pregnant or lactating, or planned to become pregnant in the near future.
3. Persons who have problems with electrocardiogram test such as arrhythmia.
4. Persons who take medicine (example: sleeping pills, anti-allergic drugs, hormone drugs, laxative, antiflatulent, and other medicines)
5. Persons who routinely take quasi-drugs and healthy foods.
6. Persons who have severe allergic disease as pollen allergy, rhinitis, atopic dermatitis.
7. Persons who have possibilities for emerging allergy to foods and cosmetics.
8. Current smoker
9. Persons who have received a cosmetic medicine (cosmetic surgery, injection of collagen, laser treatment, etc.)
10. Patients with atopic dermatitis.
11. Persons who are participate in the other clinical studies
12. Patients with vascular function disorder.
13. Persons who have severe poor circulation.
14. Persons who are judged as unsuitable for the study by the investigator for other reason.
Target sample size 18

Research contact person
Name of lead principal investigator Yoshinori Sugiyama
Organization Kao Corporation
Division name Health Beauty Products Research
Address 2-1-3, Bunka, Sumida-ku, Tokyo
TEL 03-5630-9441
Email sugiyama.yoshinori@kao.co.jp

Public contact
Name of contact person Sachie Ueda
Organization Kao Corporation
Division name Health Beauty Products Research
Address 2-1-3, Bunka, Sumida-ku, Tokyo
TEL 03-5630-9441
Homepage URL
Email ueda.sachie@kao.co.jp

Sponsor
Institute Kao Corporation
Institute
Department

Funding Source
Organization Kao Corporation
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s) None

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 花王株式会社 ヘルスビューティー研究所
(Kao Corporation, Health Beauty Products Research)

Other administrative information
Date of disclosure of the study information
2015 Year 11 Month 02 Day

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 10 Month 16 Day
Anticipated trial start date
2015 Year 11 Month 02 Day
Last follow-up date
2015 Year 12 Month 21 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2015 Year 10 Month 22 Day
Last modified on
2016 Year 10 Month 21 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022495